InVivoPlus anti-mouse TIM-3 (CD366)
BP0115
ApplicationsFlow Cytometry, Neutralisation/Blocking
Product group Antibodies
Overview
- SupplierBio X Cell
- Product NameInVivoPlus anti-mouse TIM-3 (CD366)
- Delivery Days Customer7
- ApplicationsFlow Cytometry, Neutralisation/Blocking
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDRMT3-23
- Concentration4-11 mg/ml
- Estimated Purity>95%
- HostRat
- IsotypeIgG2a
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Liu JF, Wu L, Yang LL, et al. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. J Exp Clin Cancer Res. 2018,37(1):44. doi: 10.1186/s13046-018-0713-7Read this paper
- Kurtulus S, Sakuishi K, Ngiow SF, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015,125(11):4053-62. doi: 10.1172/JCI81187Read this paper
- Ngiow SF, Young A, Jacquelot N, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015,75(18):3800-11. doi: 10.1158/0008-5472.CAN-15-1082Read this paper
- Tripathi S, Chabtini L, Dakle PJ, et al. Effect of TIM-3 Blockade on the Immunophenotype and Cytokine Profile of Murine Uterine NK Cells. PLoS One. 2015,10(4):e0123439. doi: 10.1371/journal.pone.0123439Read this paper
- Erickson JJ, Rogers MC, Hastings AK, et al. Programmed death-1 impairs secondary effector lung CD8⁺ T cells during respiratory virus reinfection. J Immunol. 2014,193(10):5108-17. doi: 10.4049/jimmunol.1302208Read this paper
- Mittal D, Young A, Stannard K, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014,74(14):3652-8. doi: 10.1158/0008-5472.CAN-14-0957Read this paper
- Dolina JS, Braciale TJ, Hahn YS. Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology. 2014,59(4):1351-65. doi: 10.1002/hep.26938Read this paper
- Dietze KK, Zelinskyy G, Liu J, et al. Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads. PLoS Pathog. 2013,9(12):e1003798. doi: 10.1371/journal.ppat.1003798Read this paper
- McGray AJ, Hallett R, Bernard D, et al. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther. 2014,22(1):206-18. doi: 10.1038/mt.2013.255Read this paper
- Zelinskyy G, Myers L, Dietze KK, et al. Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J Immunol. 2011,187(7):3730-7. doi: 10.4049/jimmunol.1101612Read this paper
